AstraZeneca has announced its plans to construct a $1.5 billion manufacturing facility in Singapore, according to Channel News Asia. This new project is aimed at producing antibody-drug conjugates (ADCs) and targeted cancer therapies. 

The Singapore Economic Development Board (EDB) will support this facility, which is slated to be the company's first end-to-end ADC production site. 

CEO Pascal Soriot expressed enthusiasm for this investment, citing Singapore's reputation for excellence in advanced health facility manufacturing. 

On AstraZeneca's side, the expansion into Singapore aligns with its massive strategy of diversifying its supply chain, which has included previous expansions into markets like China, Indonesia, and India. 

READ NEXT: BioNTech Embarks on Breast Cancer Precision Drug Late-Stage Trial, Challenging AstraZeneca

New AstraZeneca Facility in Singapore

Notably, ADCs, engineered antibodies that target and kill tumor cells, are at the forefront of cancer treatment innovation. 

The facility's construction, scheduled to commence by the end of 2024, signifies AstraZeneca's commitment to Singapore's biomedical sciences industry, a crucial contributor to the nation's economy. 

With operations projected to begin in 2029, the facility aims to achieve zero carbon emissions from its inception, marking a significant step towards sustainable pharmaceutical manufacturing.

Besides Singapore, AstraZeneca is also looking to expand in France with a nearly $1 billion investment together with Pfizer, per VCPost.

READ MORE: J&J, AstraZeneca COVID-19 Vaccines Uncover Autoimmune Link to Rare Blood Clots, Paving Way for Future Vaccine Strategies